Nuvation Bio Inc. (NUVB) — Analysis Summary
Nuvation Bio Inc. (NUVB) has a market cap of $2.20B with year-over-year revenue growth of +699.0%. Net margin stands at -325.3%. The stock trades at a P/E ratio of -15.1.
Key Takeaways
- Revenue changed +699.0% year-over-year
- Net margin of -325.3%
- P/E ratio of -15.1
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, NUVB posted revenue growth of +699.0% and trades at a P/E of -15.1.
Nuvation Bio Inc. (NUVB)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -8.9x — earnings do not cover interest payments
Operating margin at -105.0% — severe operating losses
Net margin at -102.1% — losses exceed revenue (possible one-time charges)
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
307
Headquarters
NEW YORK, NY
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.